Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics

Pancreatic cancer is one of the most lethal tumors, and reliable detection of early-stage pancreatic cancer and risk diseases for pancreatic cancer is essential to improve the prognosis. As 260 genes were previously reported to be upregulated in invasive ductal adenocarcinoma of pancreas (IDACP) cells, quantification of the corresponding proteins in plasma might be useful for IDACP diagnosis. Therefore, the purpose of the present study was to identify plasma biomarkers for early detection of IDACP by using two proteomics strategies: antibody-based proteomics and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics. Among the 260 genes, we focused on 130 encoded proteins with known function for which antibodies were available. Twenty-three proteins showed values of the area under the curve (AUC) of more than 0.8 in receiver operating characteristic (ROC) analysis of reverse-phase protein array (RPPA) data of IDACP patients compared with healthy controls, and these proteins were selected as biomarker candidates. We then used our high-throughput selected reaction monitoring or multiple reaction monitoring (SRM/MRM) methodology, together with an automated sample preparation system, micro LC and auto analysis system, to quantify these candidate proteins in plasma from healthy controls and IDACP patients on a large scale. The results revealed that insulin-like growth factor-binding protein (IGFBP)2 and IGFBP3 have the ability to discriminate IDACP patients at an early stage from healthy controls, and IGFBP2 appeared to be increased in risk diseases of pancreatic malignancy, such as intraductal papillary mucinous neoplasms (IPMNs). Furthermore, diagnosis of IDACP using the combination of carbohydrate antigen 19–9 (CA19-9), IGFBP2 and IGFBP3 is significantly more effective than CA19-9 alone. This suggests that IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of IDACP patients.

[1]  Jin‐Young Jang,et al.  Biomarker Development for Intraductal Papillary Mucinous Neoplasms Using Multiple Reaction Monitoring Mass Spectrometry. , 2016, Journal of proteome research.

[2]  Tracey L Marsh,et al.  Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms , 2015, Scientific Reports.

[3]  Sheng Pan,et al.  Proteomics analysis of bodily fluids in pancreatic cancer , 2015, Proteomics.

[4]  L. Le Marchand,et al.  Comparison of plasma levels of obesity-related biomarkers among Japanese populations in Tokyo, Japan, São Paulo, Brazil, and Hawaii, USA , 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[5]  K. Boucher,et al.  Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[6]  Christoph H. Borchers,et al.  Mass spectrometry based biomarker discovery, verification, and validation — Quality assurance and control of protein biomarker assays , 2014, Molecular oncology.

[7]  R. Baxter,et al.  IGF binding proteins in cancer: mechanistic and clinical insights , 2014, Nature Reviews Cancer.

[8]  J. Wong,et al.  Screening and early detection of pancreatic cancer in high risk population. , 2014, World journal of gastroenterology.

[9]  H. Langen,et al.  Antibody‐based proteomics and biomarker research—Current status and limitations , 2014, Proteomics.

[10]  G. Werther,et al.  IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells , 2014, Oncogene.

[11]  Christoph H Borchers,et al.  Method and platform standardization in MRM-based quantitative plasma proteomics. , 2013, Journal of proteomics.

[12]  Christoph H Borchers,et al.  Multiplexed MRM‐based quantitation of candidate cancer biomarker proteins in undepleted and non‐enriched human plasma , 2013, Proteomics.

[13]  T. Terasaki,et al.  Fluids and Barriers of the Cns , 2022 .

[14]  M. Masuda,et al.  Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. , 2013, Japanese journal of clinical oncology.

[15]  T. Terasaki,et al.  Quantitative targeted absolute proteomics-based large-scale quantification of proline-hydroxylated α-fibrinogen in plasma for pancreatic cancer diagnosis. , 2013, Journal of proteome research.

[16]  S. Batra,et al.  Early diagnosis of pancreatic cancer: challenges and new developments. , 2012, Biomarkers in medicine.

[17]  S. Weroha,et al.  The insulin-like growth factor system in cancer. , 2012, Endocrinology and metabolism clinics of North America.

[18]  Juncong Yang,et al.  MRM‐based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma , 2012, Proteomics.

[19]  David R Goodlett,et al.  Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. , 2012, Journal of proteome research.

[20]  S. Tsugane,et al.  Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia , 2012, International Journal of Obesity.

[21]  Caroline Dive,et al.  Statistical Considerations of Optimal Study Design for Human Plasma Proteomics and Biomarker Discovery , 2012, Journal of proteome research.

[22]  F. Clavel-Chapelon,et al.  Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition , 2012, British Journal of Cancer.

[23]  T. Terasaki,et al.  Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. , 2011, Journal of pharmaceutical sciences.

[24]  N. Sata,et al.  Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[25]  J. Timms,et al.  Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS. , 2011, Methods.

[26]  A. Hoffman,et al.  IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. , 2011, Endocrinology.

[27]  N. Sata,et al.  Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray , 2011, Cancer science.

[28]  U. Ballehaninna,et al.  Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review , 2011, Indian journal of surgical oncology.

[29]  Ruedi Aebersold,et al.  On the development of plasma protein biomarkers. , 2011, Journal of proteome research.

[30]  Kristin L Cheek,et al.  Depletion of abundant plasma proteins and limitations of plasma proteomics. , 2010, Journal of proteome research.

[31]  S. Tsugane,et al.  Interaction between adiponectin and leptin influences the risk of colorectal adenoma. , 2010, Cancer research.

[32]  Yoshiro Saito,et al.  Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment* , 2010, Molecular & Cellular Proteomics.

[33]  N. Moriyama,et al.  Visceral fat volume and the prevalence of colorectal adenoma. , 2009, American journal of epidemiology.

[34]  N. Sata,et al.  Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics. , 2009, The Journal of biological chemistry.

[35]  Tetsuya Terasaki,et al.  Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria , 2008, Pharmaceutical Research.

[36]  Ruedi Aebersold,et al.  Quantitative Proteomics Analysis Reveals That Proteins Differentially Expressed in Chronic Pancreatitis Are Also Frequently Involved in Pancreatic Cancer*S , 2007, Molecular & Cellular Proteomics.

[37]  R. Kannagi.  Carbohydrate antigen sialyl Lewis a--its pathophysiological significance and induction mechanism in cancer progression. , 2007, Chang Gung medical journal.

[38]  S. Tsugane,et al.  Serum triglycerides and colorectal adenoma in a case–control study among cancer screening examinees (Japan) , 2006, Cancer Causes & Control.

[39]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[40]  R. Aebersold,et al.  Quantitative proteomic profiling of pancreatic cancer juice , 2006, Proteomics.

[41]  Ian Humphery-Smith,et al.  A human proteome project with a beginning and an end , 2004, Proteomics.

[42]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[43]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[44]  E. Karna,et al.  Serum and tissue level of insulin‐like growth factor‐I (IGF‐I) and IGF‐I binding proteins as an index of pancreatitis and pancreatic cancer , 2002, International journal of experimental pathology.

[45]  A. Hoeflich,et al.  Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? , 2001, Cancer research.

[46]  S. Mohan,et al.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.

[47]  James D. Evans,et al.  Serum levels of insulin-like growth factors (IGF-I and IGF-II) and their binding protein (IGFBP-3) are not elevated in pancreatic cancer , 1997, International journal of pancreatology : official journal of the International Association of Pancreatology.

[48]  R. Baxter.  Circulating binding proteins for the insulinlike growth factors , 1993, Trends in Endocrinology & Metabolism.

[49]  R. Baxter,et al.  Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. , 1990, The Journal of clinical endocrinology and metabolism.

[50]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[51]  D. Bentley.  Primary structure of human complement component C2. Homology to two unrelated protein families. , 1986, The Biochemical journal.

[52]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[53]  R. Vanbogelen,et al.  A multiplex serum protein assay for determining the probability of colorectal cancer. , 2012, American journal of cancer research.

[54]  中村 透.  Genome-wide cDNA microarray analysis of gene-expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection , 2004 .

[55]  D. Henson,et al.  Liver, gallbladder, extrahepatic bile ducts, and pancreas , 1995, Cancer.